Search

Your search keyword '"Wong, Yien Ning Sophia"' showing total 112 results

Search Constraints

Start Over You searched for: Author "Wong, Yien Ning Sophia" Remove constraint Author: "Wong, Yien Ning Sophia"
112 results on '"Wong, Yien Ning Sophia"'

Search Results

2. Identification of urine derived lymphocytes as a non-invasive measure of the tumour immune microenvironment in bladder cancer

3. Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.

4. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

5. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

6. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

7. The T cell differentiation landscape is shaped by tumour mutations in lung cancer

11. Escape from nonsense-mediated decay associates with anti-tumor immunogenicity

12. Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

13. Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

14. Supplementary Figure from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors

15. Supplementary Table from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors

16. Supplementary Data from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors

17. Body composition and lung cancer-associated cachexia in TRACERx

18. The evolution of non-small cell lung cancer metastases in TRACERx

19. The evolution of lung cancer and impact of subclonal selection in TRACERx

20. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

21. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

22. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

23. Abstract 1591: Convergence of antigenic diversity and Tex-cell stability fatally constrains immune surveillance in non-small cell lung cancer (TRACERx) and HIV-1 infection (Protocol C)

24. Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors

25. Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London Hospital

26. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

27. Abstract LB004: Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial

28. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors

29. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

31. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

32. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

33. Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe

34. Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective

35. Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience

36. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

37. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe

38. Intratumoural (IT) evolutionary landscape of high-risk prostate cancer and outcome: The PROGENY (PROstate cancer GENomic heterogeneitY) study of genomic and immune parameters.

39. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer

40. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies

41. Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).

42. Fc-Optimized Anti-CD25 depletes tumor-infiltrating regulatory T Cells and synergizes with PD-1 Blockade to eradicate established tumors

43. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment

44. Characterisation of the TCR repertoire in NSCLC to reveal the relationship between TCR heterogeneity and genetic heterogeneity that is influenced by mutational load and is associated with disease recurrence.

45. Systematic evaluation of the immune microenvironment of neuroendocrine tumours

46. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution

48. Defining the mechanisms of response and resistance to anti-PD-1 therapy: An exploratory phase II study of pembrolizumab in advanced melanoma (ADAPTeM).

49. Preoperative staging of the axilla.

50. Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer

Catalog

Books, media, physical & digital resources